Pathogenic immune mechanisms at the neuromuscular synapse: The role of specific antibody-binding epitopes in myasthenia gravis

Journal of Internal Medicine

Volumn 275, Issue 1, 2014, Pages 12-26

  Huijbers, M G ^a   Lipka, A F ^a   Plomp, J J ^a   Niks, E H ^a   van der Maarel, S M ^a   Verschuuren, J J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Acetylcholine receptor; Autoimmunity; Epitope mapping; Muscle specific kinase; Myasthenia gravis; Neuromuscular junction

Indexed keywords

AUTOANTIBODY; CHOLINERGIC RECEPTOR; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C5; EPITOPE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; IMMUNOSUPPRESSIVE AGENT; LIPOPROTEIN RECEPTOR; LIPOPROTEIN RECEPTOR-RELATED PROTEIN 4; UNCLASSIFIED DRUG;

ANTIGENIC MODULATION; CROSS LINKING; DISEASE COURSE; EATON LAMBERT SYNDROME; EPITOPE MAPPING; HUMAN; IMMUNE SYSTEM; LIGAND BINDING; MEMBRANE DAMAGE; MYASTHENIA GRAVIS; NEUROMUSCULAR SYNAPSE; PATHOGENESIS; POSTSYNAPTIC MEMBRANE; PRIORITY JOURNAL; REVIEW; THYMECTOMY;

ACETYLCHOLINE RECEPTOR; AUTOIMMUNITY; EPITOPE MAPPING; MUSCLE-SPECIFIC KINASE; MYASTHENIA GRAVIS; NEUROMUSCULAR JUNCTION;

ANTIGEN-ANTIBODY REACTIONS; AUTOANTIBODIES; AUTOIMMUNITY; EPITOPE MAPPING; EPITOPES; HUMANS; IMMUNOGLOBULIN G; MYASTHENIA GRAVIS; MYASTHENIA GRAVIS, AUTOIMMUNE, EXPERIMENTAL; NEUROMUSCULAR JUNCTION; RECEPTORS, CHOLINERGIC; THERAPIES, INVESTIGATIONAL;

EID: 84890219823     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12163     Document Type: Review

References (144)

1. Lennon VA, Lindstrom JM, Seybold ME. Experimental autoimmune myasthenia: a model of myasthenia gravis in rats and guinea pigs. J Exp Med 1975; 141: 1365-75.
2. Lindstrom JM, Engel AG, Seybold ME, Lennon VA, Lambert EH. Pathological mechanisms in experimental autoimmune myasthenia gravis. II. Passive transfer of experimental autoimmune myasthenia gravis in rats with anti-acetylcholine receptor antibodies. J Exp Med 1976; 144: 739-53.
3. Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 1976; 26: 1054-9.
4. Carr AS, Cardwell CR, McCarron PO, McConville J. A systematic review of population based epidemiological studies in Myasthenia Gravis. BMC Neurol 2010; 10: 46.
5. Muller-Hermelink HK, Marx A. Thymoma. Curr Opin Oncol 2000; 12: 426-33.
6. Scadding GK, Vincent A, Newsom-Davis J, Henry K. Acetylcholine receptor antibody synthesis by thymic lymphocytes: correlation with thymic histology. Neurology 1981; 31: 935-43.
7. Salmon AM, Bruand C, Cardona A, Changeux JP, Berrih-Aknin S. An acetylcholine receptor α-subunit promoter confers intrathymic expression in transgenic mice. Implications for tolerance of a transgenic selfantigen and for autoreactivity in myasthenia gravis. J Clin Invest 1998; 101: 2340-50.
8. Blalock A, Mason MF, Morgan HJ, Riven SS. Myasthenia gravis and tumors of the thymic region. Report of a case in which the tumor was removed. Ann Surg 1939; 110: 544-59.
9. Giraud M, Taubert R, Vandiedonck C et al. An IRF8-binding promoter variant and AIRE control CHRNA1 promiscuous expression in thymus. Nature 2007; 448: 934-7.
10. Vincent A, Newsom-Davis J. Acetylcholine receptor antibody characteristics in myasthenia gravis. I. Patients with generalized myasthenia or disease restricted to ocular muscles. Clin Exp Immunol 1982; 49: 257-65.
11. Rodgaard A, Nielsen FC, Djurup R, Somnier F, Gammeltoft S. Acetylcholine receptor antibody in myasthenia gravis: predominance of IgG subclasses 1 and 3. Clin Exp Immunol 1987; 67: 82-8.
12. Engel AG, Arahata K. The membrane attack complex of complement at the endplate in myasthenia gravis. Ann N Y Acad Sci 1987; 505: 326-32.
13. Drachman DB, Angus CW, Adams RN, Michelson JD, Hoffman GJ. Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation. N Engl J Med 1978; 298: 1116-22.
14. Drachman DB, Adams RN, Josifek LF, Self SG. Functional activities of autoantibodies to acetylcholine receptors and the clinical severity of myasthenia gravis. N Engl J Med 1982; 307: 769-75.
15. Almon RR, Andrew CG, Appel SH. Serum globulin in myasthenia gravis: inhibition of alpha-bungarotoxin binding to acetylcholine receptors. Science 1974; 186: 55-7.
16. Hara H, Hayashi K, Ohta K, Itoh N, Nishitani H, Ohta M. Detection and characterization of blocking-type anti-acetylcholine receptor antibodies in sera from patients with myasthenia gravis. Clin Chem 1993; 39: 2053-7.
17. Lefvert AK, Cuenoud S, Fulpius BW. Binding properties and subclass distribution of anti-acetylcholine receptor antibodies in myasthenia gravis. J Neuroimmunol 1981; 1: 125-35.
18. Whiting PJ, Vincent A, Newsom-Davis J. Acetylcholine receptor antibody characteristics in myasthenia gravis. Fractionation of alpha-bungarotoxin binding site antibodies and their relationship to IgG subclass. J Neuroimmunol 1983; 5: 1-9.
19. Vernet-Der GB, Morel E, Bach JF. Heterogeneity of antibodies directed against the alpha-bungarotoxin binding site on human acetylcholine receptor and severity of myasthenia gravis. J Neuroimmunol 1986; 12: 65-74.
20. Beroukhim R, Unwin N. Three-dimensional location of the main immunogenic region of the acetylcholine receptor. Neuron 1995; 15: 323-31.
21. Tzartos SJ, Barkas T, Cung MT et al. Anatomy of the antigenic structure of a large membrane autoantigen, the muscle-type nicotinic acetylcholine receptor. Immunol Rev 1998; 163: 89-120.
22. Tzartos SJ, Seybold ME, Lindstrom JM. Specificities of antibodies to acetylcholine receptors in sera from myasthenia gravis patients measured by monoclonal antibodies. Proc Natl Acad Sci U S A 1982; 79: 188-92.
23. Tzartos SJ, Morel E, Efthimiadis A et al. Fine antigenic specificities of antibodies in sera from patients with D-penicillamine-induced myasthenia gravis. Clin Exp Immunol 1988; 74: 80-6.
24. Wintzen AR, Plomp JJ, Molenaar PC et al. Acquired slow-channel syndrome: a form of myasthenia gravis with prolonged open time of the acetylcholine receptor channel. Ann Neurol 1998; 44: 657-64.
25. Masuda T, Motomura M, Utsugisawa K et al. Antibodies against the main immunogenic region of the acetylcholine receptor correlate with disease severity in myasthenia gravis. J Neurol Neurosurg Psychiatry 2012; 83: 935-40.
26. Barkas T, Mauron A, Roth B, Alliod C, Tzartos SJ, Ballivet M. Mapping the main immunogenic region and toxin-binding site of the nicotinic acetylcholine receptor. Science 1987; 235: 77-80.
27. Gullick WJ, Lindstrom JM. Mapping the binding of monoclonal antibodies to the acetylcholine receptor from Torpedo californica. Biochemistry 1983; 22: 3312-20.
28. Saedi MS, Anand R, Conroy WG, Lindstrom J. Determination of amino acids critical to the main immunogenic region of intact acetylcholine receptors by in vitro mutagenesis. FEBS Lett 1990; 267: 55-9.
29. Luo J, Lindstrom J. Antigenic structure of the human muscle nicotinic acetylcholine receptor main immunogenic region. J Mol Neurosci 2010; 40: 217-20.
30. Tzartos SJ, Lindstrom JM. Monoclonal antibodies used to probe acetylcholine receptor structure: localization of the main immunogenic region and detection of similarities between subunits. Proc Natl Acad Sci U S A 1980; 77: 755-9.
31. Conroy WG, Saedi MS, Lindstrom J. TE671 cells express an abundance of a partially mature acetylcholine receptor alpha subunit which has characteristics of an assembly intermediate. J Biol Chem 1990; 265: 21642-51.
32. Wahlsten JL, Lindstrom JM, Ostlie N, Wu XD, Conti-Tronconi BM. Myasthenia gravis: effect on antibody binding of conservative substitutions of amino acid residues forming the main immunogenic region of the nicotinic acetylcholine receptor. J Recept Res 1993; 13: 863-79.
33. Luo J, Taylor P, Losen M, de Baets MH, Shelton GD, Lindstrom J. Main immunogenic region structure promotes binding of conformation-dependent myasthenia gravis autoantibodies, nicotinic acetylcholine receptor conformation maturation, and agonist sensitivity. J Neurosci 2009; 29: 13898-908.
34. Luo J, Lindstrom J. Myasthenogenicity of the main immunogenic region and endogenous muscle nicotinic acetylcholine receptors. Autoimmunity 2012; 45: 245-52.
35. Tzartos S, Hochschwender S, Vasquez P, Lindstrom J. Passive transfer of experimental autoimmune myasthenia gravis by monoclonal antibodies to the main immunogenic region of the acetylcholine receptor. J Neuroimmunol 1987; 15: 185-94.
36. Vanderlugt CJ, Miller SD. Epitope spreading. Curr Opin Immunol 1996; 8: 831-6.
37. Vincent A, Jacobson L, Shillito P. Response to human acetylcholine receptor alpha 138-199: determinant spreading initiates autoimmunity to self-antigen in rabbits. Immunol Lett 1994; 39: 269-75.
38. Wang HB, Shi FD, Li H, Chambers BJ, Link H, Ljunggren HG. Anti-CTLA-4 antibody treatment triggers determinant spreading and enhances murine myasthenia gravis. J Immunol 2001; 166: 6430-6.
39. Feferman T, Im SH, Fuchs S, Souroujon MC. Breakage of tolerance to hidden cytoplasmic epitopes of the acetylcholine receptor in experimental autoimmune myasthenia gravis. J Neuroimmunol 2003; 140: 153-8.
40. Tzartos SJ, Remoundos M. Detection of antibodies directed against the cytoplasmic region of the human acetylcholine receptor in sera from myasthenia gravis patients. Clin Exp Immunol 1999; 116: 146-52.
41. Hoyer LW, Trabold NC. The significance of erythrocyte antigen site density. II. Hemolysis. J Clin Invest 1971; 50: 1840-6.
42. Wong JT, Colvin RB. Bi-specific monoclonal antibodies: selective binding and complement fixation to cells that express two different surface antigens. J Immunol 1987; 139: 1369-74.
43. Aarli JA, Lefvert AK, Tonder O. Thymoma-specific antibodies in sera from patients with myasthenia gravis demonstrated by indirect haemagglutination. J Neuroimmunol 1981; 1: 421-7.
44. Agius MA, Zhu S, Kirvan CA et al. Rapsyn antibodies in myasthenia gravis. Ann N Y Acad Sci 1998; 841: 516-21.
45. Helgeland G, Petzold A, Hoff JM, Gilhus NE, Plant GT, Romi FR. Anti-Heat Shock Protein 70 antibody levels are increased in myasthenia gravis and Guillain-Barre syndrome. J Neuroimmunol 2010; 225: 180-3.
46. Ohta M, Ohta K, Itoh N, Kurobe M, Hayashi K, Nishitani H. Anti-skeletal muscle antibodies in the sera from myasthenic patients with thymoma: identification of anti-myosin, actomyosin, actin, and alpha-actinin antibodies by a solid-phase radioimmunoassay and a western blotting analysis. Clin Chim Acta 1990; 187: 255-64.
47. Williams CL, Lennon VA. Thymic B lymphocyte clones from patients with myasthenia gravis secrete monoclonal striational autoantibodies reacting with myosin, alpha actinin, or actin. J Exp Med 1986; 164: 1043-59.
48. Yamamoto T, Sato T, Sugita H. Antifilamin, antivinculin, and antitropomyosin antibodies in myasthenia gravis. Neurology 1987; 37: 1329-33.
49. Yu M, Johnson JM, Tuohy VK. A predictable sequential determinant spreading cascade invariably accompanies progression of experimental autoimmune encephalomyelitis: a basis for peptide-specific therapy after onset of clinical disease. J Exp Med 1996; 183: 1777-88.
50. Luo J, Kuryatov A, Lindstrom JM. Specific immunotherapy of experimental myasthenia gravis by a novel mechanism. Ann Neurol 2010; 67: 441-51.
51. Engel AG, Lambert EH, Howard FM. Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations. Mayo Clin Proc 1977; 52: 267-80.
52. Hoedemaekers A, Graus Y, van Vriesman B, De BM. Age- and sex-related resistance to chronic experimental autoimmune myasthenia gravis (EAMG) in Brown Norway rats. Clin Exp Immunol 1997; 107: 189-97.
53. de Baets MH, Verschuuren J, Daha MR, van Breda Vriesman PJ. Effects of the rate of acetylcholine receptor synthesis on the severity of experimental autoimmune myasthenia gravis. Immunol Res 1988; 7: 200-11.
54. Tüzün E, Christadoss P. Complement associated pathogenic mechanisms in myasthenia gravis. Autoimmun Rev 2013; 12: 904-11.
55. Stanley EF, Drachman DB. Effect of myasthenic immunoglobulin on acetylcholine receptors of intact mammalian neuromuscular junctions. Science 1978; 200: 1285-7.
56. Barchan D, Souroujon MC, Im SH, Antozzi C, Fuchs S. Antigen-specific modulation of experimental myasthenia gravis: nasal tolerization with recombinant fragments of the human acetylcholine receptor alpha-subunit. Proc Natl Acad Sci U S A 1999; 96: 8086-91.
57. Drachman DB, Okumura S, Adams RN, McIntosh KR. Oral tolerance in myasthenia gravis. Ann N Y Acad Sci 1996; 778: 258-72.
58. Karachunski PI, Ostlie NS, Okita DK, Conti-Fine BM. Prevention of experimental myasthenia gravis by nasal administration of synthetic acetylcholine receptor T epitope sequences. J Clin Invest 1997; 100: 3027-35.
59. Ma CG, Zhang GX, Xiao BG, Link J, Olsson T, Link H. Suppression of experimental autoimmune myasthenia gravis by nasal administration of acetylcholine receptor. J Neuroimmunol 1995; 58: 51-60.
60. Shi FD, Li H, Wang H et al. Mechanisms of nasal tolerance induction in experimental autoimmune myasthenia gravis: identification of regulatory cells. J Immunol 1999; 162: 5757-63.
61. Wang ZY, Huang J, Olsson T, He B, Link H. B cell responses to acetylcholine receptor in rats orally tolerized against experimental autoimmune myasthenia gravis. J Neurol Sci 1995; 128: 167-74.
62. Maiti PK, Feferman T, Im SH, Souroujon MC, Fuchs S. Immunosuppression of rat myasthenia gravis by oral administration of a syngeneic acetylcholine receptor fragment. J Neuroimmunol 2004; 152: 112-20.
63. Im SH, Barchan D, Souroujon MC, Fuchs S. Role of tolerogen conformation in induction of oral tolerance in experimental autoimmune myasthenia gravis. J Immunol 2000; 165: 3599-605.
64. Xiao BG, Link H. Mucosal tolerance: a two-edged sword to prevent and treat autoimmune diseases. Clin Immunol Immunopathol 1997; 85: 119-28.
65. Araga S, Leboeuf RD, Blalock JE. Prevention of experimental autoimmune myasthenia gravis by manipulation of the immune network with a complementary peptide for the acetylcholine receptor. Proc Natl Acad Sci U S A 1993; 90: 8747-51.
66. Araga S, Blalock JE. Use of complementary peptides and their antibodies in B-cell-mediated autoimmune disease: prevention of experimental autoimmune myasthenia gravis with a peptide vaccine. Immunomethods 1994; 5: 130-5.
67. Araga S, Xu L, Nakashima K, Villain M, Blalock JE. A peptide vaccine that prevents experimental autoimmune myasthenia gravis by specifically blocking T cell help. FASEB J 2000; 14: 185-96.
68. Kostelidou K, Trakas N, Zouridakis M et al. Expression and characterization of soluble forms of the extracellular domains of the beta, gamma and epsilon subunits of the human muscle acetylcholine receptor. FEBS J 2006; 273: 3557-68.
69. Psaridi-Linardaki L, Mamalaki A, Remoundos M, Tzartos SJ. Expression of soluble ligand- and antibody-binding extracellular domain of human muscle acetylcholine receptor alpha subunit in yeast Pichia pastoris. Role of glycosylation in alpha-bungarotoxin binding. J Biol Chem 2002; 277: 26980-6.
70. Tzartos SJ, Bitzopoulou K, Gavra I et al. Antigen-specific apheresis of pathogenic autoantibodies from myasthenia gravis sera. Ann N Y Acad Sci 2008; 1132: 291-9.
71. Lagoumintzis G, Zisimopoulou P, Kordas G, Lazaridis K, Poulas K, Tzartos SJ. Recent approaches to the development of antigen-specific immunotherapies for myasthenia gravis. Autoimmunity 2010; 43: 436-45.
72. van der Neut Kolfschoten M, Schuurman J, Losen M et al. 2007. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange Science 317: 1554-7.
73. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001; 7: 365-8.
74. Evoli A, Tonali PA, Padua L et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 2003; 126: 2304-11.
75. Bartoccioni E, Scuderi F, Augugliaro A et al. HLA class II allele analysis in MuSK-positive myasthenia gravis suggests a role for DQ5. Neurology 2009; 72: 195-7.
76. Niks EH, Kuks JB, Roep BO et al. Strong association of MuSK antibody positive myasthenia gravis and HLA-DR14-DQ5. Neurology 2006; 66: 1772-4.
77. Evoli A, Blianchi MR, Riso R et al. Response to therapy in myasthenia gravis with anti-MuSK antibodies. Ann N Y Acad Sci 2008; 1132: 76-83.
78. Hatanaka Y, Hemmi S, Morgan MB et al. Nonresponsiveness to anticholinesterase agents in patients with MuSK-antibody-positive MG. Neurology 2005; 65: 1508-9.
79. Díaz-Manera J, Martínez-Hernández E, Querol L et al. Long-lasting treatment effect of rituximab in MuSK myasthenia. Neurology 2012; 78: 189-93.
80. McConville J, Farrugia ME, Beeson D et al. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol 2004; 55: 580-4.
81. Niks EH, Van LY, Leite MI et al. Clinical fluctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1. J Neuroimmunol 2008; 195: 151-6.
82. Klooster R, Plomp JJ, Huijbers MG et al. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice. Brain 2012; 135: 1081-101.
83. Aalberse RC, Stapel SO, Schuurman J, Rispens T. Immunoglobulin G4: an odd antibody. Clin Exp Allergy 2009; 39: 469-77.
84. Ohta K, Shigemoto K, Fujinami A, Maruyama N, Konishi T, Ohta M. Clinical and experimental features of MuSK antibody positive MG in Japan. Eur J Neurol 2007; 14: 1029-34.
85. Takamori M, Nakamura T, Motomura M. Antibodies against Wnt receptor of muscle-specific tyrosine kinase in myasthenia gravis. J Neuroimmunol 2013; 254: 183-6.
86. Luo ZG, Wang Q, Zhou JZ et al. Regulation of AChR clustering by Dishevelled interacting with MuSK and PAK1. Neuron 2002; 35: 489-505.
87. Stiegler AL, Burden SJ, Hubbard SR. Crystal structure of the frizzled-like cysteine-rich domain of the receptor tyrosine kinase MuSK. J Mol Biol 2009; 393: 1-9.
88. Wu H, Xiong WC, Mei L. To build a synapse: signaling pathways in neuromuscular junction assembly. Development 2010; 137: 1017-33.
89. Stiegler AL, Burden SJ, Hubbard SR. Crystal structure of the agrin-responsive immunoglobulin-like domains 1 and 2 of the receptor tyrosine kinase MuSK. J Mol Biol 2006; 364: 424-33.
90. Zhang W, Coldefy AS, Hubbard SR, Burden SJ. Agrin binds to the N-terminal region of Lrp4 protein and stimulates association between Lrp4 and the first immunoglobulin-like domain in muscle-specific kinase (MuSK). J Biol Chem 2011; 286: 40624-30.
91. Cole RN, Ghazanfari N, Ngo ST, Gervasio OL, Reddel SW, Phillips WD. Patient autoantibodies deplete postsynaptic muscle-specific kinase leading to disassembly of the ACh receptor scaffold and myasthenia gravis in mice. J Physiol 2010; 588: 3217-29.
92. Amenta AR, Creely HE, Mercado ML et al. Biglycan is an extracellular MuSK binding protein important for synapse stability. J Neurosci 2012; 32: 2324-34.
93. Cartaud A, Strochlic L, Guerra M et al. MuSK is required for anchoring acetylcholinesterase at the neuromuscular junction. J Cell Biol 2004; 165: 505-15.
94. Kim N, Stiegler AL, Cameron TO et al. Lrp4 is a receptor for Agrin and forms a complex with MuSK. Cell 2008; 135: 334-42.
95. Zhang B, Luo S, Wang Q, Suzuki T, Xiong WC, Mei L. LRP4 serves as a coreceptor of agrin. Neuron 2008; 60: 285-97.
96. Kawakami Y, Ito M, Hirayama M et al. Anti-MuSK autoantibodies block binding of collagen Q to MuSK. Neurology 2011; 77: 1819-26.
97. Dechiara TM, Bowen DC, Valenzuela DM et al. The receptor tyrosine kinase MuSK is required for neuromuscular junction formation in vivo. Cell 1996; 85: 501-12.
98. Kim N, Burden SJ. MuSK controls where motor axons grow and form synapses. Nat Neurosci 2008; 11: 19-27.
99. Plomp JJ, Van Kempen GT, de Baets MB, Graus YM, Kuks JB, Molenaar PC. Acetylcholine release in myasthenia gravis: regulation at single end-plate level. Ann Neurol 1995; 37: 627-36.
100. Viegas S, Jacobson L, Waters P et al. Passive and active immunization models of MuSK-Ab positive myasthenia: electrophysiological evidence for pre and postsynaptic defects. Exp Neurol 2012; 234: 506-12.
101. Mori S, Kubo S, Akiyoshi T et al. Antibodies against muscle-specific kinase impair both presynaptic and postsynaptic functions in a murine model of myasthenia gravis. Am J Pathol 2012; 180: 798-810.
102. Niks EH, Kuks JB, Wokke JH et al. Pre- and postsynaptic neuromuscular junction abnormalities in musk myasthenia. Muscle Nerve 2010; 42: 283-8.
103. Selcen D, Fukuda T, Shen XM, Engel AG. Are MuSK antibodies the primary cause of myasthenic symptoms? Neurology 2004; 62: 1945-50.
104. Yumoto N, Kim N, Burden SJ. Lrp4 is a retrograde signal for presynaptic differentiation at neuromuscular synapses. Nature 2012; 489: 438-42.
105. Higuchi O, Hamuro J, Motomura M, Yamanashi Y. Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol 2011; 69: 418-22.
106. Zhang B, Tzartos JS, Belimezi M et al. Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch Neurol 2012; 69: 445-51.
107. Cole RN, Reddel SW, Gervasio OL, Phillips WD. Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction. Ann Neurol 2008; 63: 782-9.
108. Mori S, Yamada S, Kubo S et al. Divalent and monovalent autoantibodies cause dysfunction of MuSK by distinct mechanisms in a rabbit model of myasthenia gravis. J Neuroimmunol 2012; 244: 1-7.
109. Pevzner A, Schoser B, Peters K et al. Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis. J Neurol 2012; 259: 427-35.
110. Zong Y, Zhang B, Gu S et al. Structural basis of agrin-LRP4-MuSK signaling. Genes Dev 2012; 26: 247-58.
111. Motomura M, Johnston I, Lang B, Vincent A, Newsom-Davis J. An improved diagnostic assay for Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 1995; 58: 85-7.
112. Nakao YK, Motomura M, Fukudome T et al. Seronegative Lambert-Eaton myasthenic syndrome: study of 110 Japanese patients. Neurology 2002; 59: 1773-5.
113. O'Neill JH, Murray NM, Newsom-Davis J. The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain 1988; 111: 577-96.
114. Titulaer MJ, Wirtz PW, Kuks JB et al. The Lambert-Eaton myasthenic syndrome 1988-2008: a clinical picture in 97 patients. J Neuroimmunol 2008; 201-202: 153-8.
115. Titulaer MJ, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: tumor versus nontumor forms. Ann N Y Acad Sci 2008; 1132: 129-34.
116. Wirtz PW, Smallegange TM, Wintzen AR, Verschuuren JJ. Differences in clinical features between the Lambert-Eaton myasthenic syndrome with and without cancer: an analysis of 227 published cases. Clin Neurol Neurosurg 2002; 104: 359-63.
117. Titulaer MJ, Maddison P, Sont JK et al. Clinical Dutch-English Lambert-Eaton Myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS. J Clin Oncol 2011; 29: 902-8.
118. Wirtz PW, Sotodeh M, Nijnuis M et al. Difference in distribution of muscle weakness between myasthenia gravis and the Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 2002; 73: 766-8.
119. O'Suilleabhain P, Low PA, Lennon VA. Autonomic dysfunction in the Lambert-Eaton myasthenic syndrome: serologic and clinical correlates. Neurology 1998; 50: 88-93.
120. Prior C, Lang B, Wray D, Newsom-Davis J. Action of Lambert-Eaton myasthenic syndrome IgG at mouse motor nerve terminals. Ann Neurol 1985; 17: 587-92.
121. Kim YI. Passive transfer of the Lambert-Eaton myasthenic syndrome: neuromuscular transmission in mice injected with plasma. Muscle Nerve 1985; 8: 162-72.
122. Komai K, Iwasa K, Takamori M. Calcium channel peptide can cause an autoimmune-mediated model of Lambert-Eaton myasthenic syndrome in rats. J Neurol Sci 1999; 166: 126-30.
123. Lecky BR. Transient neonatal Lambert-Eaton syndrome. J Neurol Neurosurg Psychiatry 2006; 77: 1094.
124. Roberts A, Perera S, Lang B, Vincent A, Newsom-Davis J. Paraneoplastic myasthenic syndrome IgG inhibits 45Ca2+ flux in a human small cell carcinoma line. Nature 1985; 317: 737-9.
125. Fukunaga H, Engel AG, Lang B, Newsom-Davis J, Vincent A. Passive transfer of Lambert-Eaton myasthenic syndrome with IgG from man to mouse depletes the presynaptic membrane active zones. Proc Natl Acad Sci U S A 1983; 80: 7636-40.
126. Peers C, Johnston I, Lang B, Wray D. Cross-linking of presynaptic calcium channels: a mechanism of action for Lambert-Eaton myasthenic syndrome antibodies at the mouse neuromuscular junction. Neurosci Lett 1993; 153: 45-8.
127. Lambert EH, Lennon VA. Selected IgG rapidly induces Lambert-Eaton myasthenic syndrome in mice: complement independence and EMG abnormalities. Muscle Nerve 1988; 11: 1133-45.
128. Viglione MP, O'Shaughnessy TJ, Kim YL. Inhibition of calcium currents and exocytosis by Lambert-Eaton syndrome antibodies in human lung cancer cells. J Physiol 1995; 15: 303-17.
129. Varadi G, Mori Y, Mikala G, Schwartz A. Molecular determinants of Ca2+ channel function and drug action. Trends Pharmacol Sci 1995; 16: 43-9.
130. Takamori M, Iwasa K, Komai K. Antibodies to synthetic peptides of the alpha1A subunit of the voltage-gated calcium channel in Lambert-Eaton myasthenic syndrome. Neurology 1997; 48: 1261-5.
131. Parsons KT, Kwok WW. Linear B-cell epitopes in Lambert-Eaton myasthenic syndrome defined by cell-free synthetic peptide binding. J Neuroimmunol 2002; 126: 190-5.
132. Pellkofer HL, Armbruster L, Krumbholz M et al. Lambert-eaton myasthenic syndrome differential reactivity of tumor versus non-tumor patients to subunits of the voltage-gated calcium channel. J Neuroimmunol 2008; 204: 136-9.
133. Iwasa K, Takamori M, Komai K, Mori Y. Recombinant calcium channel is recognized by Lambert-Eaton myasthenic syndrome antibodies. Neurology 2000; 54: 757-9.
134. Takamori M. Lambert-Eaton myasthenic syndrome: search for alternative autoimmune targets and possible compensatory mechanisms based on presynaptic calcium homeostasis. J Neuroimmunol 2008; 201-202: 145-52.
135. Verschuuren JJ, Dalmau J, Tunkel R et al. Antibodies against the calcium channel beta-subunit in Lambert-Eaton myasthenic syndrome. Neurology 1998; 50: 475-9.
136. Raymond C, Walker D, Bichet D et al. Antibodies against the beta subunit of voltage-dependent calcium channels in Lambert-Eaton myasthenic syndrome. Neuroscience 1999; 90: 269-77.
137. Huijbers MG, Lipka AF, Potman M et al. Antibodies to active zone protein ERC1 in Lambert-Eaton myasthenic syndrome. Hum Immunol 2013; 74: 849-51.
138. Takamori M, Motomura M, Fukudome T, Yoshikawa H. Autoantibodies against M1 muscarinic acetylcholine receptor in myasthenic disorders. Eur J Neurol 2007; 14: 1230-5.
139. Giovannini F, Sher E, Webster R, Boot J, Lang B. Calcium channel subtypes contributing to acetylcholine release from normal, 4-aminopyridine-treated and myasthenic syndrome auto-antibodies-affected neuromuscular junctions. Br J Pharmacol 2002; 136: 1135-45.
140. Lennon VA, Kryzer TJ, Griesmann GE et al. Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med 1995; 332: 1467-74.
141. Smith RG, Hamilton S, Hofmann F et al. Serum antibodies to L-type calcium channels in patients with amyotrophic lateral sclerosis. N Engl J Med 1992; 327: 1721-8.
142. Titulaer M, Klooster R, Potman M, et al. SOX antibodies in small-cell lung cancer and Lambert-Eaton myasthenic syndrome: frequency and relation with survival. J Clin Oncol 2009; 27: 4260-67.
143. Sabater L, Titulaer MJ, Saiz A, Verschuuren JJ, Güre AO, Graus F. SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome. Neurology 2008; 70: 924-8.
144. Maddison P, Thorpe A, Silcocks P, Robertson JF, Chapman CJ. Autoimmunity to SOX2, clinical phenotype and survival in patients with small-cell lung cancer. Lung Cancer 2010; 70: 335-9.